pheon therapeutics ltd
pheon therapeutics ltd Company Information
Company Number
09677410
Next Accounts
Dec 2025
Shareholders
research corporation technologies inc
atlas venture fund xii l p
View AllGroup Structure
View All
Industry
Research and experimental development on biotechnology
Registered Address
innovation house innovation way, discovery park, sandwich, kent, CT13 9FF
Website
www.femtogenix.compheon therapeutics ltd Estimated Valuation
Pomanda estimates the enterprise value of PHEON THERAPEUTICS LTD at £2m based on a Turnover of £1.5m and 1.36x industry multiple (adjusted for size and gross margin).
pheon therapeutics ltd Estimated Valuation
Pomanda estimates the enterprise value of PHEON THERAPEUTICS LTD at £0 based on an EBITDA of £-21.7m and a 5.35x industry multiple (adjusted for size and gross margin).
pheon therapeutics ltd Estimated Valuation
Pomanda estimates the enterprise value of PHEON THERAPEUTICS LTD at £31.3m based on Net Assets of £17.5m and 1.79x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Pheon Therapeutics Ltd Overview
Pheon Therapeutics Ltd is a live company located in sandwich, CT13 9FF with a Companies House number of 09677410. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in July 2015, it's largest shareholder is research corporation technologies inc with a 19.3% stake. Pheon Therapeutics Ltd is a established, small sized company, Pomanda has estimated its turnover at £1.5m with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Pheon Therapeutics Ltd Health Check
Pomanda's financial health check has awarded Pheon Therapeutics Ltd a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 3 areas for improvement. Company Health Check FAQs
4 Strong
2 Regular
3 Weak
Size
annual sales of £1.5m, make it smaller than the average company (£3.5m)
- Pheon Therapeutics Ltd
£3.5m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Pheon Therapeutics Ltd
- - Industry AVG
Production
with a gross margin of 54.5%, this company has a comparable cost of product (54.5%)
- Pheon Therapeutics Ltd
54.5% - Industry AVG
Profitability
an operating margin of -1468.4% make it less profitable than the average company (-7.8%)
- Pheon Therapeutics Ltd
-7.8% - Industry AVG
Employees
with 9 employees, this is below the industry average (46)
9 - Pheon Therapeutics Ltd
46 - Industry AVG
Pay Structure
on an average salary of £79.9k, the company has an equivalent pay structure (£79.9k)
- Pheon Therapeutics Ltd
£79.9k - Industry AVG
Efficiency
resulting in sales per employee of £164.1k, this is more efficient (£124.5k)
- Pheon Therapeutics Ltd
£124.5k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Pheon Therapeutics Ltd
- - Industry AVG
Creditor Days
its suppliers are paid after 385 days, this is slower than average (53 days)
- Pheon Therapeutics Ltd
53 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Pheon Therapeutics Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 540 weeks, this is more cash available to meet short term requirements (34 weeks)
540 weeks - Pheon Therapeutics Ltd
34 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 8.5%, this is a lower level of debt than the average (50.9%)
8.5% - Pheon Therapeutics Ltd
50.9% - Industry AVG
PHEON THERAPEUTICS LTD financials
Pheon Therapeutics Ltd's latest turnover from March 2024 is estimated at £1.5 million and the company has net assets of £17.5 million. According to their latest financial statements, Pheon Therapeutics Ltd has 9 employees and maintains cash reserves of £16.8 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||
| Other Income Or Grants | ||||||||
| Cost Of Sales | ||||||||
| Gross Profit | ||||||||
| Admin Expenses | ||||||||
| Operating Profit | ||||||||
| Interest Payable | ||||||||
| Interest Receivable | ||||||||
| Pre-Tax Profit | ||||||||
| Tax | ||||||||
| Profit After Tax | ||||||||
| Dividends Paid | ||||||||
| Retained Profit | ||||||||
| Employee Costs | ||||||||
| Number Of Employees | 9 | 9 | 6 | 8 | 9 | 9 | 10 | 8 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 961 | 20,043 | 45,214 | 120,739 | 197,287 | 236,290 | 239,579 | 114,819 |
| Intangible Assets | 1 | 79 | 157 | 235 | 313 | |||
| Investments & Other | ||||||||
| Debtors (Due After 1 year) | ||||||||
| Total Fixed Assets | 961 | 20,043 | 45,214 | 120,740 | 197,366 | 236,447 | 239,814 | 115,132 |
| Stock & work in progress | ||||||||
| Trade Debtors | 35,000 | 40,000 | 5,000 | 3,840 | ||||
| Group Debtors | 44,733 | |||||||
| Misc Debtors | 2,311,584 | 2,406,449 | 110,708 | 146,401 | 144,536 | 377,672 | 355,169 | 190,380 |
| Cash | 16,769,985 | 13,389,911 | 23,502,060 | 221,049 | 871,647 | 321,002 | 177,398 | 1,229,762 |
| misc current assets | ||||||||
| total current assets | 19,081,569 | 15,876,093 | 23,652,768 | 372,450 | 1,020,023 | 698,674 | 532,567 | 1,420,142 |
| total assets | 19,082,530 | 15,896,136 | 23,697,982 | 493,190 | 1,217,389 | 935,121 | 772,381 | 1,535,274 |
| Bank overdraft | ||||||||
| Bank loan | ||||||||
| Trade Creditors | 710,500 | 924,318 | 252,049 | 51,430 | 238,584 | 49,282 | 80,978 | 23,773 |
| Group/Directors Accounts | 179,082 | |||||||
| other short term finances | ||||||||
| hp & lease commitments | ||||||||
| other current liabilities | 722,859 | 908,794 | 116,382 | 75,451 | 71,413 | 74,940 | 28,352 | 21,173 |
| total current liabilities | 1,612,441 | 1,833,112 | 368,431 | 126,881 | 309,997 | 124,222 | 109,330 | 44,946 |
| loans | ||||||||
| hp & lease commitments | ||||||||
| Accruals and Deferred Income | ||||||||
| other liabilities | 2,458,718 | 1,641,041 | ||||||
| provisions | 33,552 | 40,196 | 26,674 | 23,026 | ||||
| total long term liabilities | 2,458,718 | 1,674,593 | 40,196 | 26,674 | 23,026 | |||
| total liabilities | 1,612,441 | 1,833,112 | 368,431 | 2,585,599 | 1,984,590 | 164,418 | 136,004 | 67,972 |
| net assets | 17,470,089 | 14,063,024 | 23,329,551 | -2,092,409 | -767,201 | 770,703 | 636,377 | 1,467,302 |
| total shareholders funds | 17,470,089 | 14,063,024 | 23,329,551 | -2,092,409 | -767,201 | 770,703 | 636,377 | 1,467,302 |
| Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Profit | ||||||||
| Depreciation | 7,932 | 30,571 | 79,808 | 73,934 | 72,520 | 63,927 | 30,510 | 6,873 |
| Amortisation | 1 | 78 | 78 | 78 | 78 | 78 | ||
| Tax | ||||||||
| Stock | ||||||||
| Debtors | -174,598 | 2,335,474 | 150,708 | 3,025 | -229,296 | 22,503 | 164,789 | 190,380 |
| Creditors | -213,818 | 672,269 | 252,049 | -187,154 | 189,302 | -31,696 | 57,205 | 23,773 |
| Accruals and Deferred Income | -185,935 | 792,412 | 116,382 | 4,038 | -3,527 | 46,588 | 7,179 | 21,173 |
| Deferred Taxes & Provisions | -33,552 | -6,644 | 13,522 | 3,648 | 23,026 | |||
| Cash flow from operations | ||||||||
| Investing Activities | ||||||||
| capital expenditure | ||||||||
| Change in Investments | ||||||||
| cash flow from investments | ||||||||
| Financing Activities | ||||||||
| Bank loans | ||||||||
| Group/Directors Accounts | 179,082 | |||||||
| Other Short Term Loans | ||||||||
| Long term loans | ||||||||
| Hire Purchase and Lease Commitments | ||||||||
| other long term liabilities | 817,677 | 1,641,041 | ||||||
| share issue | ||||||||
| interest | ||||||||
| cash flow from financing | ||||||||
| cash and cash equivalents | ||||||||
| cash | 3,380,074 | -10,112,149 | 23,502,060 | -650,598 | 550,645 | 143,604 | -1,052,364 | 1,229,762 |
| overdraft | ||||||||
| change in cash | 3,380,074 | -10,112,149 | 23,502,060 | -650,598 | 550,645 | 143,604 | -1,052,364 | 1,229,762 |
pheon therapeutics ltd Credit Report and Business Information
Pheon Therapeutics Ltd Competitor Analysis
Perform a competitor analysis for pheon therapeutics ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in CT13 area or any other competitors across 12 key performance metrics.
pheon therapeutics ltd Ownership
PHEON THERAPEUTICS LTD group structure
Pheon Therapeutics Ltd has no subsidiary companies.
Ultimate parent company
PHEON THERAPEUTICS LTD
09677410
pheon therapeutics ltd directors
Pheon Therapeutics Ltd currently has 9 directors. The longest serving directors include Mr Shaun Kirkpatrick (Sep 2015) and President Michael Gladstone (Mar 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Shaun Kirkpatrick | United Kingdom | 56 years | Sep 2015 | - | Director |
| President Michael Gladstone | United States | 38 years | Mar 2022 | - | Director |
| Dr Rogier Rooswinkel | Netherlands | 41 years | Mar 2022 | - | Director |
| Mr Jonathan Tobin | United Kingdom | 42 years | Mar 2022 | - | Director |
| Dr Rogier Rooswinkel | Netherlands | 41 years | Mar 2022 | - | Director |
| Mr Jeffery Albers | United Kingdom | 53 years | Jan 2023 | - | Director |
| Dr Cyrus Mozayeni | United States | 50 years | Jul 2023 | - | Director |
| Mr Cariad Chester | United States | 33 years | Apr 2024 | - | Director |
| Mr Enoch Kariuki | United Kingdom | 43 years | Sep 2024 | - | Director |
P&L
March 2024turnover
1.5m
+37%
operating profit
-21.7m
0%
gross margin
54.5%
+1.13%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
17.5m
+0.24%
total assets
19.1m
+0.2%
cash
16.8m
+0.25%
net assets
Total assets minus all liabilities
pheon therapeutics ltd company details
company number
09677410
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
July 2015
age
10
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
March 2024
previous names
femtogenix ltd (August 2022)
accountant
KRESTON REEVES LLP
auditor
-
address
innovation house innovation way, discovery park, sandwich, kent, CT13 9FF
Bank
-
Legal Advisor
-
pheon therapeutics ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to pheon therapeutics ltd.
pheon therapeutics ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for PHEON THERAPEUTICS LTD. This can take several minutes, an email will notify you when this has completed.
pheon therapeutics ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
